Targeting cytokines in inflammatory bowel disease

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) involves complex cytokine dysregulation.
• Current IBD therapies target specific cytokines or signaling pathways.

Purpose of the Study:

• To review current and emerging cytokine-targeting strategies for IBD.
• To highlight the potential of combination anti-cytokine therapies in IBD management.

Main Methods:

• Literature review of cytokine-targeting agents in IBD.
• Analysis of therapeutic approaches including regulatory T cell transfer, cytokine/receptor blockade, and kinase inhibition.
• Examination of emerging combination therapy strategies.

Main Results:

• Cytokine targeting is a validated clinical strategy for IBD.
• Multiple agents like anti-IL-12/23, anti-sIL-6R, anti-IL-36R, and JAK inhibitors are used.
• Combination therapy represents a novel approach for enhanced efficacy.

Conclusions:

• Cytokine modulation is central to IBD treatment.
• Combining different anti-cytokine agents offers a promising avenue for future IBD therapies.
• Restoring cytokine balance is key to managing IBD effectively.